about
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomasEvaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastomaThe genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade gliomaPhase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas.A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma.Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma.Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma."Occult" post-contrast signal enhancement in pediatric diffuse intrinsic pontine glioma is the MRI marker of angiogenesis?MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine gliomaA phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.Effect of time from diagnosis to start of radiotherapy on children with diffuse intrinsic pontine gliomaEffective treatment of cerebral mucormycosis associated with brain surgeryIncidental diagnosis of diffuse intrinsic pontine glioma in children.Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma.Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007Necrosis after craniospinal irradiation: results from a prospective series of children with central nervous system embryonal tumors.Sequencing of local therapy affects the pattern of treatment failure and survival in children with atypical teratoid rhabdoid tumors of the central nervous system.Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem gliomaPhase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas.Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas.Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS)Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis.Phase I study of everolimus in pediatric patients with refractory solid tumors.Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain TumoHigh-grade astrocytoma in very young children.Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420.Malignant transformation of low-grade gliomas in children: lessons learned from rare medical events.Quantitative longitudinal evaluation of diaschisis-related cerebellar perfusion and diffusion parameters in patients with supratentorial hemispheric high-grade gliomas after surgery.Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous.Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial.An adolescent with HTLV-I-associated adult T cell leukemia treated with interferon-alfa and zidovudine.Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.Diffusion tensor imaging of brainstem tumors: axonal degeneration of motor and sensory tractsMalignant progression of a peripheral nerve sheath tumor in the setting of rhabdoid tumor predisposition syndrome
P50
Q24629777-4DAABC0D-CF0B-444D-9043-058BF6D99BC6Q30578179-94F2C78D-17AF-45EA-A10C-B14506CC6C81Q33377386-D90C4224-C420-4AA7-B3AE-F32153E4F9E4Q33702910-0F64D93B-FFFB-45F9-B9ED-B10B7BC36CD6Q33751426-4C5A4283-AC63-4D6F-9991-489FB7993B53Q33825938-961CEF02-B9D6-4160-8507-D89BFD58870BQ34332525-D68FC224-8F40-4C8F-811E-6830EC85E001Q34339843-63C172CD-7C25-4933-B875-8EBEF2CE5590Q34480641-B889CF62-45C0-4D8E-B3FF-563496A2502DQ34488803-3477B13E-6965-412E-98F9-B30006B15B02Q34598854-906A4071-BBF1-4CA1-8C93-0090BE756B7EQ34598895-5025F1F0-4F30-417D-85A4-B78F268754B4Q34722457-DE699E8D-ED1A-453F-8E6D-F4C810D47973Q35021664-60119E0C-AAE5-4B53-B795-3F3D84A320A8Q35230772-F3EEFF00-E8BC-4DA5-B769-5777AA04492BQ35449392-2945612C-2363-4458-A02D-1A2DF082FF99Q35514221-2B85359E-1E07-4518-AF1A-EE4B70698407Q35532490-5DEDD7E0-050E-42FE-ACD1-558101FD9FDDQ36058482-5E413397-51DE-430B-92EE-A3A8C330D009Q36486272-C39FF792-1567-463B-8F36-0C515AA3BE86Q36489422-CD0DA255-5C32-4248-99E8-D12344792C92Q36926772-A817FD4C-BE27-4EA3-B785-F1E067981BBDQ36936139-F769E877-3700-4EDA-AD78-88750946B5CBQ36951069-27D4C359-27B1-4679-83DA-07CDA1E22C24Q37238690-C84E9B37-75A1-4B24-8721-2312E5A15720Q37689492-87168BAE-62CB-4867-B703-45640A28D454Q38262398-EA33666E-3E50-45E2-B1F8-56BB83AD3552Q38273428-DF90FFCD-7332-4729-8BBB-CC25362D8E69Q46942053-F516D880-7FA7-4327-89E1-90144EC64299Q48102977-361461B0-0721-41D2-A89D-34FC2795E78CQ48143873-210C3A59-2B96-4243-B144-84A76B45020BQ48256059-B42D33EA-9FB8-4E2A-B82C-6BE636A8DC64Q48336316-8526AF03-041E-4A72-A25F-108C4BB2F84AQ48721495-950FBDFF-406D-45E9-AF86-50AABB7B51F1Q50079534-FD3A5B6E-5C16-42A6-A455-7CD49A28C5A4Q53495225-46881B36-6840-4E02-B142-73759290A8D8Q55240528-D0B5C735-03F9-4624-850A-D328ED8EE313Q55456561-56F3A6DE-F7A8-4CD8-A99E-DAF1037D1CCFQ80983958-C3422E46-9079-4F33-BFC0-4BDFCBE36B26Q87986889-5E35DA94-BC9D-417F-B075-8862429AAF96
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alberto Broniscer
@ast
Alberto Broniscer
@en
Alberto Broniscer
@es
Alberto Broniscer
@nl
type
label
Alberto Broniscer
@ast
Alberto Broniscer
@en
Alberto Broniscer
@es
Alberto Broniscer
@nl
prefLabel
Alberto Broniscer
@ast
Alberto Broniscer
@en
Alberto Broniscer
@es
Alberto Broniscer
@nl
P106
P21
P31
P496
0000-0001-9646-0463